Emcure Pharmaceuticals Limited is a significant Indian pharmaceutical company that develops, manufactures, and markets a wide range of pharmaceutical products in a variety of therapeutic categories around through the world. Emcure Pharmaceuticals IPO will hit the market in November 2021.
Table of Contents
About Emcure Pharmaceuticals
Emcure Pharmaceuticals was the 12th biggest pharmaceutical business in India and the biggest pharmaceutical firm in India in the gynaecological, blood related, and HIV antivirals therapeutic categories in the Financial Year 2021 as per CRISIL.
They are a research-and-development-driven firm with an unique product portfolio that comprises orals, injectables, and biologics, and an mRNA platform.
Using mRNA platform they are presently creating a COVID-19 vaccine, that has allowed us to achieve a wide range of target markets in over 70 nations, with a significant presence in Europe and Canada.
They are led by a Promoter Group with substantial pharmaceutical industry expertise who are backed up by an experienced management staff.
Growth
They’ve grown quickly in recent years, and They’re now one of India’s fastest-growing pharmaceutical organizations, as determined by the rise in their pharmaceutical product revenues.
From 2019 and 2021, their total sales in India increased at a CAGR of 11.28 percent, from 32,856.00 million to 40,686.00 million, surpassing the entire rise in sales in the Indian pharmaceutical business, which increased at a CAGR of 5.78 percent.
They think their home market advantage derives from their existing presence in most of the key therapeutic categories, such as gynaecological, cardiovascular, vitamins, minerals, and nutrients, oncology/anti-neoplastic, HIV, and blood-related.
Presence
Seven of their products were also included in the top 300 pharmaceutical product brands in the domestic market, according to sales.
They are now concentrating on the neurology, anti-diabetics, and respiratory therapeutic areas, as well as expanding their therapeutic domain by leveraging their leading positions in their main therapeutic fields to enter neighbouring therapeutic regions.
With a field team of over 4,600 people, they had a pan-India marketing and distribution presence.
Along with their solid position in India, a number of international corporations have engaged into co-marketing and in-licensing arrangements with them for the sale and distribution of their products in India.
Manufacturing Facilities
In India, they have 14 production plants. Their facilities can produce a wide range of pharmaceutical and biopharmaceutical products, comprising oral solids, oral liquids, injectables (lipid, liposomal, lyophilized injectables), biologics, vaccines, and complicated APIs (chiral molecules and cytotoxic compounds).
Several regulatory agencies, such as the USFDA, MHRA (United Kingdom), Health Canada, and EDQM, have given their clearance to their facilities (Europe).
Their capacity to make their own APIs has also helped them to achieve a high level of vertical integration, enabling them to source APIs at a cheap cost.
Emcure Pharmaceuticals IPO
Emcure Pharmaceuticals Limited, headquartered in Pune has submitted Draft Red Herring Prospectus(DRHP) to Securities and Exchange Board of India(SEBI) for initial public offering (IPO) of INR 1,100 crore value equity shares & 18,168,356 equity shares on 18 August 2021.
The Offer includes INR 1,100 crore value fresh equity shares and There is an offer for sale (OFS) of 18,168,356 equity shares by the promoters mentioned in the DRHP.
They are now waiting for approval from Securities and Exchange Board of India(SEBI) to float the initial public offering (IPO) in the market.
Financials Trends
| Particulars | For the year/period ended ( in Cr.) | ||||
|---|---|---|---|---|---|
| 31-Mar-21 | 31-Mar-20 | 31-Mar-19 | |||
| Total Assets | 6,807.40 | 6,004.06 | 5,810.44 | ||
| Total Revenue | 6,091.81 | 5,130.86 | 4,815.59 | ||
| Profit After Tax | 418.59 | 100.61 | 202.97 | ||
Basic and Diluted Earnings Per Share
| Financial Period | Basic EPS (in INR) | Diluted EPS (in INR) | Weight |
| Financial Year 2021 | 21.68 | 21.68 | 3 |
| Financial Year 2020 | 4.62 | 4.62 | 2 |
| Financial Year 2019 | 10.47 | 10.47 | 1 |
| Weighted Average | 14.13 | 14.13 |
Objects of the Issue
- Prepayment / repayment of all or a portion of the outstanding borrowings of the company to be availed on consolidated basis.
- To meet common corporate objectives.
Basis of the offer
They think the following are some of the fundamental elements that contribute into determining the Offer Price:
- Their business is well-positioned to take advantage of a dominant position in the domestic market.
- In international markets, they have a large, diverse, and rapidly growing product portfolio.
- Capabilities in research and development Driving a Diversified Product Portfolio
- Developing Brands Proven Abilities
- Production Capabilities are Broad and Specialized.
- De-Risked Business Strategy with Diversified Revenue Sources
- Emphasis on ESG (Environmental, Social, and Governance).
- A leadership team and board of directors that are highly skilled, seasoned, and innovative.
Emcure Pharmaceuticals IPO Peer Comparison
| S. No. | Face Value | Company Name | PE |
| 1 | 10 | Abbott India Limited | 53.79 |
| 2 | 2 | Alkem Laboratories Limited | 25.28 |
| 3 | 5 | Biocon Limited | 66.12 |
| 4 | 2 | Cipla Limited | 32.80 |
| 5 | 5 | Dr. Reddy’s Laboratories Limited | 46.08 |
| 6 | 5 | Torrent Pharmaceuticals Limited | 40.43 |
Emcure Pharmaceuticals IPO Details
| IPO Opening Date | November 2021 |
| IPO Closing Date | November 2021 |
| Issue Type | Book Building |
| Face Value | 10 per share |
| IPO Price | 0 to 0 per equity share |
| Market Lot | – |
| Min Order Quantity | – |
| Listing At | BSE, NSE |
| Issue Size | – |
| Fresh Issue | 1,100 Crore |
| Offer for Sale | 18,168,356 equity shares |
Emcure Pharmaceuticals IPO Date
Emcure Pharmaceuticals IPO opening date is November 2021, and the closing date is November 2021. The Emcure Pharmaceuticals issue may list in November 2021.
| IPO Opening Date | November 2021 |
| IPO Closing Date | November 2021 |
| Basis of Allotment Date | November 2021 |
| Initiation of Refunds | November 2021 |
| Credit of Shares to Demat Account | November 2021 |
| IPO Listing Date | November 2021 |
Basis of Allotment
| Type | % of Offer | Basis of Allotment |
|---|---|---|
| Qualified Institutional Buyer | 50 |
Roughly
equivalent
|
| Non Institutional Investor | 15 |
Roughly
equivalent
|
| Retail | 35 | Minimum level of 1 lot, based on availability, for every shareholder. |
Emcure Pharmaceuticals IPO Allotment Status
Allotment of equity stocks subject to the Fresh Issue and transfer of the Promoter Selling Shareholders’ OFS Stocks to the winning Bidders subject to the Offer for Sale. Nevertheless, the status of the allotment has yet to be revealed.
Here, you can find the Allotment Status of Emcure Pharmaceuticals IPO.
Emcure Pharmaceuticals IPO GMP
Emcure Pharmaceuticals IPO Grey Market Premium is 0.
| Date | GMP (in Rs) | Subject to Sauda | Kostak (in Rs) |
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 |
Emcure Pharmaceuticals IPO Review
Emcure Pharmaceuticals IPO review will depend on the price band. Whenever it will be announced we will update you regarding review of Emcure Pharmaceuticals IPO is good or bad.
Emcure Pharmaceuticals IPO Risk
- The COVID-19 pandemic, also known as a broad public health emergency, might have a negative influence on their company.
- A halt or slowdown in their production or R&D operations might have a negative impact on their business.
- Their failure to correctly predict demand for our offerings and handle inventories might be detrimental to their business.
- Their Company, its Promoters, Subsidiaries, Directors, and Group Companies are all involved in ongoing legal procedures.
- Their failure to implement their business strategy and growth plans successfully might have a negative impact on their company.
- Failure to successfully integrate any of their acquired businesses might cause operational issues and have a negative impact on their business.
Other Threats
- Our business may suffer if they do not preserve and expand the number of arrangements they have for marketing and distribution of their products.
- They are exposed to the risks associated with currency rate changes.
- Their business might suffer if they accidentally infringe on the patents of others.
- Since their R&D and production methods and materials are very combustible and toxic, they are at risk of loss due to fire, mishaps, and other dangers.
- They are subject to counterparty credit risk, and any payment delays might have a negative impact on their operations.
- Some of their corporate documents, such as those pertaining to RoC filings, are untraceable.
- The availability of counterfeit medications, such as drugs passed off as their medicines by others, might harm their reputation.
Business Approach
They think that their strategic and calibrated marketing strategy has enabled them to strengthen their position in existing areas while also expanding into new markets in a cost-effective and profitable way.
For example, one of their target areas in Europe is the hospital sector, which is a significant market for their complicated injectables medicines like Cidofovir, BiCNU, and Treprostinil, for which they encounter comparatively little competition.
In a lot of nations, they operate subsidiaries and branch offices that help them coordinate and manage their worldwide activities. They also offer our range of distinctive products in over 70 countries across the world.
R&D
They are a research-and-development-driven firm, and their fundamental strength is their capacity to study, develop, and manufacture specialised pharmaceutical products in-house for high-growth therapeutic areas. They divide Their product offerings into two categories:
- Formulations, where They focus on pharmaceutical goods in different dosage forms and innovative drug delivery methods with increased efficacy & biopharmaceuticals, where they’ve effectively built microbial and mammalian-based platforms and launched several niche products using them.
- Active pharmaceutical ingredients (“APIs”), where they consider ourselves to be a chiral chemistry pioneer and have established considerable competence in complicated APIs, antiretrovirals and oncology products.
Team
They had 501 highly trained scientists on staff, as well as five specialised R&D centres. They had been issued 161 patents and had 98 patent applications pending in numerous countries as of the same date, and they had filed 98 DMFs for APIs to various regulatory authorities across the world.
They have a proven track record of creating distinctive product portfolios across a variety of platforms, including chiral compounds, complex APIs, biologics, and innovative drug delivery systems.
As per CRISIL, they have a portfolio of 11 chiral compounds, six of which were released for the first time in India. They are confident in their ability to acquire and master these approaches and skill sets.
Emcure Pharmaceuticals IPO Brokerage views
- Yes Securities : Not Updated
- Choice Brokering: Not Updated
- Axis Securities: Not Updated
- IIFL Securities: Not Updated
- Trade swift: Not Updated
- Anand Rathi : Not Updated
- ICICI Securities: Not Updated
Emcure Pharmaceuticals IPO Subscription Status
| Date | Day | QIB | NII | Retail | Employees | Total Subscription |
| November 2021 | 1 | |||||
| November 2021 | 2 | |||||
| November 2021 | 3 |
Promoters
- Satish Mehta
- Sunil Mehta
Promoters’ Holding
| Pre Issue Share Holding | 48.05 % |
| Post Issue Share Holding |
Emcure Pharmaceuticals IPO Prospectus
Contact Details
Emcure Pharmaceuticals Limited
Emcure House, T-184, M.I.D.C., Bhosari,
Pune – 411 026, Maharashtra, India.
Tel: +(91) 20 35010000/ 40700000
E-mail: [email protected]
Website: www.emcure.com
Registrar
Link Intime India Private Limited
C-101, 1st Floor, 247 Park
L.B.S. Marg, Vikhroli West,
Mumbai 400 083
Maharashtra, India
Tel: +91 22 4918 6200
E-mail: [email protected]
Website: www.linkintime.co.in
Lead Manager(s)
- Axis Capital Limited
- BofA Securities India Limited
- Credit Suisse Securities (India) Private Limited
- JM Financial Limited
- BOB Capital Markets Limited
We hope we are able to answer all your questions about Emcure Pharmaceuticals IPO. If you don’t have a Demat account, open it now with Zerodha best trading app.
Disclaimer
The reference of IPO Grey Market Premium (IPO GMP) is only valid for the date specified in the header.
On the IPO Grey Market, we do not purchase or sell IPO forms.
The Kostak Rate is the profit earned by selling an IPO application (in an off-market transaction) to somebody else before the issue is allotted or listed.
Do not subscribe to an IPO based solely on the premium price, as it may alter at any time before to the listing. Only consider the fundamentals of the companies when subscribing.
The GMP rates for IPOs are based on market intelligence. Please keep in mind that these IPO GMP rates may vary by geography and market.
Note:
We do not engage in grey market trading or facilitate the purchase or sale of IPO forms. We don’t endorse such activities at all. We are sticky against such activities & never advise anyone to trade in grey market at all.
FAQ
Emcure Pharmaceuticals IPO Opening Date?
Emcure Pharmaceuticals IPO will open in November 2021.
Emcure Pharmaceuticals IPO Listing Date?
Emcure Pharmaceuticals IPO will list in November 2021.
Emcure Pharmaceuticals IPO GMP Today?
Emcure Pharmaceuticals IPO Grey Market Premium is INR 0 .
Emcure Pharmaceuticals IPO Allotment Date?
Emcure Pharmaceuticals IPO basis of allotment will be in November 2021.
Lot size for Emcure Pharmaceuticals IPO?
Lot size for Emcure Pharmaceuticals IPO is 0.
